Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

2 terminated/withdrawn out of 10 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

10%

1 trials in Phase 3/4

Results Transparency

50%

4 of 8 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1

2(40.0%)

Phase 4

1(20.0%)

N/A

1(20.0%)

Early Phase 1

1(20.0%)

5Total

Phase 1(2)

Phase 4(1)

N/A(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT05177328Phase 1Terminated

Targeted Investigation of Microbiome Elimination

Role: collaborator

NCT03389893Phase 4Terminated

Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis

Role: collaborator

NCT03038932Completed

Etiology of Eczema Herpeticum (EH)

Role: collaborator

NCT03151148Phase 1Completed

Targeted Microbiome Transplant in Atopic Dermatitis

Role: collaborator

NCT01494142Completed

Registry for the Atopic Dermatitis Research Network

Role: collaborator

NCT03168113Completed

Atopic Dermatitis (AD) and Food Allergy

Role: collaborator

NCT01429311Completed

Interferon Responses in Eczema Herpeticum

Role: collaborator

NCT01737710Not ApplicableCompleted

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study

Role: collaborator

NCT01518478Early Phase 1Completed

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot

Role: collaborator

NCT02115399Completed

ADRN Barrier/Immunoprofiling Exploratory Pilot Study

Role: collaborator

All 10 trials loaded